SCHEMBL25356354

SCHEMBL25356354

COC(=O)Cc1nn(C(C)C)c2cc(Br)ccc2c1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 4/20 0.64
▸ POLB P06746 1/20 0.38
▸ CASP3 P42574 2/20 0.36
▸ TYRO3 Q06418 2/20 0.36
▸ PDGFRA P16234 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ RXFP1 Q9HBX9 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ ELANE P08246 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ PAK4 O96013 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25431544 0.89 NLRP3 (0.59) NLRP3POLBTYRO3RXFP1SMN1; SMN2
SCHEMBL29492185 0.87 NLRP3 (0.64) NLRP3POLBTYRO3PDGFRACDK5
SCHEMBL25356861 0.81 NLRP3 (0.57) NLRP3POLBTYRO3PDGFRACDK5
SCHEMBL29492036 0.78 NLRP3 (1.00) NLRP3NTRK1
SCHEMBL29494685 0.78 NLRP3 (0.52) NLRP3POLBTYRO3PDGFRACDK5
SCHEMBL498197 0.75 ELANE (0.51) NLRP3POLBTYRO3PDGFRACDK5
SCHEMBL25356370 0.75 NLRP3 (0.53) NLRP3TYRO3PDGFRACDK5MAPK8
SCHEMBL25357485 0.74 NLRP3 (1.00) NLRP3SMN1; SMN2LMNAMAPT
SCHEMBL25357358 0.73 NLRP3 (0.48) NLRP3TYRO3PDGFRACDK5RET
SCHEMBL25360566 0.73 NLRP3 (0.48) NLRP3TYRO3PDGFRACDK5EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 — — EP disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 — — US disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063876-A1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 NLRP3 1/4885POLB 2610/4885CASP3 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback